Episode description
Episode description
Join us for a captivating interview with our guest Professor Michael Hudecek from the Universitätsklinikum Würzburg in Germany as he offers his insights on the latest advancements in CAR T-cell therapy and gene-engineered immune cell therapies.
Together with our host Dr. Isabel Olivera Martinez, they discuss the mounting real-world data on CAR T-cell treatments and how AI is helping analyze this data to design new strategies and extend CAR-T to new indications.
Discover the strides being made to predict and manage treatment-related toxicities and to make CAR T-cell therapy more accessible and affordable, including potential off-the-shelf treatments and automated manufacturing techniques.
Learn about the role of gene editing and the challenges of creating universally compatible immune cell products. Finally, gain insights from the 2024 CAR T-cell meeting, where groundbreaking clinical updates and new applications of CAR-T to autoimmune and cardiovascular diseases were showcased.
Host: Dr Isabel Olivera Martinez
Guest: Prof Michael Hudecek
This is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!
Interested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe